Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for BIKTARVY
- A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission
- Next Generation Ingestible Sensors for Medication Adherence Measurement
- microRNAs in HIV and Obesity
- Doravirine and Weight Gain in Antiretroviral Naive
- BFTAF Elderly Switch Study
- Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age
- Pharmacokinetics of Calcineurin & mTOR Inhibitors in HIV-1 Infected Kidney Transplant Recipients After Switch to BIC/FTC/TAF
- The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers
- Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH
- Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens
- A Study of JNJ-56136379 in Healthy Participants
- Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)
- Same-day Antiretroviral Therapy With BIC/F/TAF
- Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'
- Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF
- 2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial
- A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects
- A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed
- Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide After Renal Transplant
- Bictegravir/FTC/TAF for the Treatment of Primary HIV Infection
- A Test and Treat Strategy in New HIV Diagnosis.
- Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection
- Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV
- Bioequivalence of Solid/Crushed/Dissolved Forms of Biktarvy®
- Switch to TAF+FTC+BIC in HIV-1-infected Patients Over 65 Years Old at Risk of Polymedication
- Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen
- Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy
- ART Persistence in Different Body Compartments in HIV Negative MSM
- Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE
- How Does Antiretroviral Therapy Affect Coronary Atherosclerosis: A Serial CT Study
- BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) Study
- Empiric Treatment for Acute HIV in the ED
- The Late Presenter Treatment Optimisation Study
- Effects of Biktarvy on CFR in Stable HIV Patients
- Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy
- Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1
- Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)
- Optimizing the Delivery of HIV nPEP
Clinical trials list
click for details